Coinpaper
MRNA Stock Doubles After Moderna-Merck Cancer Vaccine Succeeds in Phase 3 Trial
MRNA shares surged after Moderna and Merck’s personalized cancer vaccine met key Phase 3 melanoma endpoints with no new safety concerns.
Read the full article on Coinpaper
Opens in a new tab. Cointrackx tracks this click for statistics.
Partner
